reports
- Research Team ACF
KDST + NLSP Combined Core Investment Case 29052025
We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
Eli Lilly & Co: 1 director
A director at Eli Lilly & Co sold 1,000 shares at 716.410USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Moody's Ratings assigns A2 rating to Pfizer's subsidiary notes offerin...
Moody's Ratings ("Moody's") assigned a A2 rating to the proposed euro-denominated senior unsecured notes offering by Pfizer Netherlands International Finance B.V. (PNIF BV), a wholly-owned subsidiary of Pfizer Inc. (Pfizer). We also assigned a stable outlook to PNIF BV. The A2 rating assigned to P...
- Research Team ACF
ACF Thematic Oncology Lung Cancer Cough LCC 25042025
Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
DLTR DOLLAR TREE INC.
CVGW CALAVO GROWERS INC.
CAR AVIS BUDGET GROUP INC.
A AGILENT TECHNOLOGIES INC.
MSB MESABI TRUST
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
TATT TAT TECHNOLOGIES LTD.
IIIN INSTEEL INDUSTRIES INC.
SJT SAN JUAN BASIN ROYALTY TRUST
CHCI COMSTOCK HOLDING COMPANIES
SEZI SENZIME AB
ANAB ANAPTYSBIO INC.
TIGO MILLICOM INTERNATIONAL CELLULAR S.A.
FRAF FRANKLIN FINANCIAL SERVICES CO.
OVBC OHIO VALLEY BANC CORP
NEON NEONODE INC.
SMMT SUMMIT THERAPEUTICS INC
HTZ HERTZ GLOBAL HLDGS INC
MPTI M TRON INDUSTRIES INC
NUTX NUTEX HEALTH INC
ZBIO PROSHARES ULTRAPRO SHORT NASDAQ BIOTECHNOLOGY
VRM VROOM INC
- Pelham Smithers
Viking Therapeutics Inc: 1 director
A director at Viking Therapeutics Inc bought 1,240 shares at 24.147USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
- Pelham Smithers
PSA Strategy: Japan Stock Market Quarterly for 2025 Q2
In this quarterly strategy report, we look to evaluate where we are with regards the bull market conditions, and where those indicators might be headed, factoring in the downside risks, from Trump tariffs and the US economy, BoJ actions, Japanese earnings and valuations.
AMAT APPLIED MATERIALS INC.
6146 DISCO CORPORATION
5108 BRIDGESTONE CORPORATION
7751 CANON INC.
9697 CAPCOM CO. LTD.
4519 CHUGAI PHARMACEUTICAL CO. LTD.
4755 RAKUTEN INC.
9684 SQUARE ENIX HOLDINGS CO. LTD.
8473 SBI HOLDINGS INC.
6954 FANUC CORPORATION
4324 DENTSU GROUP INC.
6861 KEYENCE CORPORATION
6869 SYSMEX CORPORATION
8306 MITSUBISHI UFJ FINANCIAL GROUP INC.
6501 HITACHI LTD.
6305 HITACHI CONSTRUCTION MACHINERY CO. LTD.
7267 HONDA MOTOR CO. LTD.
6301 KOMATSU LTD.
6503 MITSUBISHI ELECTRIC CORP.
6723 RENESAS ELECTRONICS CORPORATION
7974 NINTENDO CO. LTD.
6594 NIDEC CORPORATION
7731 NIKON CORP.
8604 NOMURA HOLDINGS INC.
7733 OLYMPUS CORP.
4666 PARK24 CO. LTD.
2371 KAKAKU.COM INC.
9984 SOFTBANK GROUP CORP.
1803 SHIMIZU CORPORATION
4063 SHIN-ETSU CHEMICAL CO LTD
6758 SONY CORPORATION
7269 SUZUKI MOTOR CORP.
1801 TAISEI CORP
6857 ADVANTEST CORP.
4186 TOKYO OHKA KOGYO CO. LTD.
8035 TOKYO ELECTRON LTD.
7203 TOYOTA MOTOR CORP.
2413 M3 INC.
2160 GNI GROUP LTD.
3659 NEXON CO. LTD.
6098 RECRUIT HOLDINGS CO. LTD.
3769 GMO PAYMENT
6460 JP SEGA SAMMY
4385 MERCARI INC.
3993 PKSHA TECHNOLOGY INC.
9434 SOFTBANK CORP.
78320 BANDAI NAMCO
45870 PEPTIDREAM INC
3491 JT GA TECHNOLOGIES
3394 JT MONEY FOWARD
6532 JT BAYCURRENT CONSULTING (6532 JT)
4483 JMDC
4180 JP APPIER GROUP
TSE: 2980 SRE HOLDINGS CORP
4194 VISIONAL INC
6526 SOCIONEXT INC
5032 JT ANYCOLOR INC
5838 RAKUTEN BANK LTD.
5253 JT COVER CORPORATION (5253 JT)
9616 JT KYORITSU MAINTENANCE (9616 JT)
Pfizer Invites Public to View and Listen to Webcast of April 29 Confer...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. Participants are advised to re...
- Research Team ACF
ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...
Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Near-Term Downside Likely Following False Breakouts Our long-term outlook remains bullish as long as the S&P 500 remains above 5770-5850 and 5600-5670 (worst case), and we are buyers at these levels. With that said, we see potential for near-term downside as the S&P 500, Nasdaq 100 (QQQ), and FANG+ (FNGS) (1) could not decisively break out to new highs, (2) display bearish false breakouts, (3) have fallen back into their 2+ month trading ranges, (4) are violating their 1+ month uptrends, and (5...
LLY ELI LILLY AND COMPANY
CFSL COCA-COLA FEMSA SAB DE CV (ADR)
JNJ JOHNSON & JOHNSON
BMY BRISTOL-MYERS SQUIBB COMPANY
AKOB EMBOTELLADORA ANDINA S.A. SERIES B ADS
FMX FOMENTO ECONOMICO MEXICANO S.A.B. DE C.V. ADS
BMTA BRITISH AMERICAN TOBACCO PLC ADS
PM PHILIP MORRIS INTERNATIONAL INC.
ABBV ABBVIE INC.
CCHGY COCA-COLA HBC AG
ABT ABBOTT LABORATORIES
AZN ASTRAZENECA PLC ADS
GSK. GLAXOSMITHKLINE PLC CEDEAR
IMBBY IMPERIAL BRANDS PLC
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Hea...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 10:30 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. The transcript and webcast replay of the discussion will be made available on our web site at within 24 hours after the end of the live discussion a...
- Jonathan Moreland
WYNN WYNN RESORTS LIMITED
TTSH TILE SHOP HOLDINGS INC.
OXBR OXBRIDGE RE HOLDINGS
NGL NGL ENERGY PARTNERS LP
HMC HARMONIC
HII HUNTINGTON INGALLS INDUSTRIES INC.
EL ESTEE LAUDER COMPANIES INC. CLASS A
CVS CVS HEALTH CORPORATION
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
BZH BEAZER HOMES USA INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
ASYS AMTECH SYSTEMS INC.
ARCC ARES CAPITAL CORPORATION
AIG AMERICAN INTERNATIONAL GROUP INC.
MDU MDU RESOURCES GROUP INC
CMCO COLUMBUS MCKINNON CORPORATION
USFD US FOODS HOLDING CORP.
FRD FRIEDMAN INDUSTRIES INC.
PLBC PLUMAS BANCORP
FBK FB FINANCIAL CORPORATION
MRUS MERUS B V
PFE PFIZER INC.
XFLT XAI OCTAGON FLOATING RATE ALTERNATIVE INCOME TERM TRUST
RCUS ARCUS BIOSCIENCES
NWPP NEW PEOPLES BANKSHARES INC.
EAF GRAFTECH INTERNATIONAL
AMCR AMCOR PLC
BFC BANK FIRST NATIONAL CORP
CBKM CONSUMERS BANCORP INC.
IDYA IDEAYA BIOSCIENCES
RZLT REZOLUTE
REYN INC.
MTCH REYNOLDS CONSUMER PRODUCTS INC.
ESOA MATCH GROUP INC.
ATAI ENERGY SERVICES OF AMERICA CORP.
FLNC ATAI LIFE SCIENCES BV
BST FLUENCE ENERGY INC
PCT BLACKROCK SCIENCE AND TECHNOLOGY TRUST
CMPO PURECYCLE TECHNOLOGIES INC
EFSI COMPOSECURE INC
LSMG EAGLE FINANCIAL SERVICES INC
SLDB LODE STAR MINING INC
RCEL SOLID BIOSCIENCES INC
MNR AVITA MEDICAL INC
OCX MACH NATURAL RESOURCES LP
FDBC ONCOCYTE CORPORATION
FIDELITY D & D BANCORP INC
Pfizer Inc: 1 director
Two Directors at Pfizer Inc sold/bought 19,764 shares at between 0.000USD and 25.650USD. The significance rating of the trade was 98/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
- Jonathan Moreland
XNCR XENCOR INC.
PBF PBF ENERGY INC. CLASS A
ORRF ORRSTOWN FINANCIAL SERVICES INC.
MKL MARKEL CORPORATION
JBLU JETBLUE AIRWAYS CORPORATION
HMC HARMONIC
HII HUNTINGTON INGALLS INDUSTRIES INC.
EL ESTEE LAUDER COMPANIES INC. CLASS A
BZH BEAZER HOMES USA INC.
BUSE FIRST BUSEY CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ARCC ARES CAPITAL CORPORATION
CBFV CB FINANCIAL SERVICES INC.
MDU MDU RESOURCES GROUP INC
MUR MURPHY OIL CORPORATION
OLN OLIN CORPORATION
CMCO COLUMBUS MCKINNON CORPORATION
HP HELMERICH & PAYNE INC.
FRD FRIEDMAN INDUSTRIES INC.
HI HILLENBRAND INC.
OVLY OAK VALLEY BANCORP
FLWS 1-800-FLOWERS.COM CL A
FBK FB FINANCIAL CORPORATION
KALV KALVISTA PHARMACEUTICALS
PFE PFIZER INC.
MPB MID PENN BANCORP INC.
NWPP NEW PEOPLES BANKSHARES INC.
EAF GRAFTECH INTERNATIONAL
NWFL NORWOOD FINANCIAL CORP.
FRAF FRANKLIN FINANCIAL SERVICES CO.
AMCR AMCOR PLC
MFON MOBIVITY HOLDINGS CORP.
PLCE THE CHILDREN'S PLACE RETAIL STORES
ALLY INC.
REYN GMAC LLC
MTCH REYNOLDS CONSUMER PRODUCTS INC.
IMNM MATCH GROUP INC.
CTOS IMMUNOME
FLNC CUSTOM TRUCK ONE SOURCE
PCT INC.
CMPO FLUENCE ENERGY INC
EFSI PURECYCLE TECHNOLOGIES INC
VGAS COMPOSECURE INC
TKO EAGLE FINANCIAL SERVICES INC
MNR VERDE CLEAN FUELS INC
BHRB TKO GROUP HOLDINGS
OCX INC.
SUNS MACH NATURAL RESOURCES LP
BURKE HERBERT FINANCIAL SERVICES CORP
ONCOCYTE CORPORATION
SUNRISE REALTY TRUST
- Jonathan Moreland
BZH BEAZER HOMES USA INC.
CMCO COLUMBUS MCKINNON CORPORATION
FBK FB FINANCIAL CORPORATION
KALV KALVISTA PHARMACEUTICALS
PFE PFIZER INC.
MPB MID PENN BANCORP INC.
AMCR AMCOR PLC
RVLV REVOLVE GROUP
PFX PHENIXFIN CORP
FLNC FLUENCE ENERGY INC
CMPO COMPOSECURE INC
ECBK ECB BANCORP INC.
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outco...
NEW YORK--(BUSINESS WIRE)-- (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), demonstrating a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo plus XTANDI in patients with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. The TALAPRO-2 results will be presented ...
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treat...
NEW YORK--(BUSINESS WIRE)-- (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for autologous hemat...
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® ...
NEW YORK & TOKYO--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced additional follow-up results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) evaluating the efficacy and safety of PADCEV ® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA® (pembrolizumab), a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). The results showed a sustained overall survival (OS) and progression-free survi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.